PD-1 Inhibitors for Hematologic Malignancies

December 7, 2014
Philippe Armand, MD, PhD

Philippe Armand, MD, PhD, senior physician, Dana-Farber Cancer Institute, discusses the utility of PD-1 inhibitors for hematologic malignancies.

Clinical Pearls

Philippe Armand, MD, PhD, senior physician, Dana-Farber Cancer Institute, discusses the utility of PD-1 inhibitors for hematologic malignancies.

  • It is unknown as to whether PD-1 inhibitors could be combined with chemotherapy or immunotherapy in hematologic malignancies.
  • Nivolumab showed efficacy in classical Hodgkin lymphoma, but it was one of the first studies to analyze the class of drugs into hematologic malignancies.

<<<

Go back to the ASH conference page